

AD _____

Award Number: DAMD17-99-1-9032

TITLE: An Experimental System to Evaluate LOH in Prostate Cancer

PRINCIPAL INVESTIGATOR: William M. Strauss, Ph.D.

CONTRACTING ORGANIZATION: University of Colorado
Boulder, CO 80309-0572

REPORT DATE: July 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20040329 028

REPORT
DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE July 2003	3. REPORT TYPE AND DATES COVERED Annual (1 Jul 2002 - 30 Jun 2003)
4. TITLE AND SUBTITLE An Experimental System to Evaluate LOH in Prostate Cancer		5. FUNDING NUMBERS DAMD17-99-1-9032
6. AUTHOR(S) William M. Strauss, Ph.D.		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Colorado Boulder, CO 80309-0572 E-Mail: strauswm@spot.Colorado.EDU		8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER
11. SUPPLEMENTARY NOTES		
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited		12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) <p>The goal of this grant is to establish a new biological system for studying the progression of prostate cancer. We propose a technology we have previously developed to help define X-chromosome inactivation to increase our understanding of the molecular biology of prostate cancer. Using a mouse model, our goal is to induce functional Loss of Heterozygosity (LOH) on a particular chromosome at various specified times during development or life span. Specifically, we plan to induce LOH only in mouse prostatic tissues. We are particularly interested in evaluating sites of allelic loss previously identified to be associated with prostate cancer (7q, 8p, 10p, 10q, 13q, 16q, 18q) in humans and understanding the effect of LOH on syntenic mouse chromosomes. We believe this approach has the potential to increase our knowledge of the acquisition and progression of prostate cancer. A systematic experimental approach for creating LOH can help define new prostate specific tumor suppressor genes. As human chromosome 8p is most frequently associated with prostate cancer (80% of primary and metastatic prostate cancers show this chromosomal variant, our mouse model system will initially focus on the development of those mouse chromosomes syntenic with human chromosome 8p. This technology would augment the positional cytogenetic approach to understanding the genetic complexity of prostate cancer.</p>		
14. SUBJECT TERMS Prostate		15. NUMBER OF PAGES 13
		16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified
		20. LIMITATION OF ABSTRACT Unlimited

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

YES Where copyrighted material is quoted, permission has been obtained to use such material.

YES Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

YES Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

 In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

 In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

William M. Staines Jr. 12/4/03
PI - Signature Date

Table of Contents

Cover.....	1
SF 298.....	2
Foreword.....	3
Table of Contents.....	4
Introduction.....	5
Body.....	5
Key Research Accomplishments.....	9
Reportable Outcomes.....	9
Conclusions.....	10
References.....	10
Appendices.....	13

5)Introduction

The goal of this grant is to establish a new biological system for studying the progression of prostate cancer. We propose a technology we have previously developed to help define X-chromosome inactivation to increase our understanding of the molecular biology of prostate cancer. Using a mouse model, our goal is to induce functional Loss of Heterozygosity (LOH) on a particular chromosome at various specified times during development or life span. Specifically, we plan to induce LOH only in mouse prostatic tissues. We are particularly interested in evaluating sites of allelic loss previously identified to be associated with prostate cancer (7q, 8p, 10p, 10q, 13q, 16q, 18q) in humans and understanding the effect of LOH on syntenic mouse chromosomes. We believe this approach has the potential to increase our knowledge of the acquisition and progression of prostate cancer. A systematic experimental approach for creating LOH can help define new prostate specific tumor suppressor genes. As human chromosome 8p is most frequently associated with prostate cancer (80% of primary and metastatic prostate cancers show this chromosomal variant, our mouse model system will initially focus on the development of those mouse chromosomes syntenic with human chromosome 8p. This technology would augment the positional cytogenetic approach to understanding the genetic complexity of prostate cancer.

6) Body

Background

Activation or inactivation of a gene may lead to carcinogenesis. Activation of genes refers to a dominant condition that results in stimulation of both growth and progression of cancer. Inactivation of genes refers to the phenomena where tumor suppressor genes (genes that normally inhibit carcinogenesis) are inactivated resulting in a loss function. Classically, these mutations are due to lesions which alter the linear sequence of a particular gene. In addition, somatic dysregulation or inappropriate gene-silencing due to methylation (where the gene is present but nonfunctional), may have similar effects.

Inactivation of a gene may occur as a result of allelic deletion where one or both copies of a locus is lost (1-4). Most frequently one copy is lost and is detected as a loss of heterozygosity (LOH). When this loss involves a tumor suppression gene, carcinogenesis may occur. In prostate cancer, several common sites of allelic loss have been identified including 7q, 8p, 10p, 10q, 13q, 16q, and 18q (1-4). The 8p arm is most frequently lost as 80% of primary and metastatic prostate cancers show this chromosomal variant (10, 11). Most allelic deletions on 8p involve large chromosomal intervals. Working from large collections of clinical specimens, researchers are attempting to define a common overlapping chromosomal region. From this overlapping region, the goal is to then identify particular genes and evaluate their relationship to prostate cancer.

This approach to allelic loss mapping is difficult if LOH is common and the lesions are complex or non-specific. The approach now used to solve this dilemma is to pursue a random search from available clinical specimens to try to strengthen the correlation of tumor phenotype and chromosome architecture. Another approach to accelerate gene identification in prostate cancer would be to experimentally test the effect of LOH for particular chromosomal regions on the development of prostate cancer. To date, this approach has not been utilized although it has the potential to greatly speed up the process of prostate cancer gene identification.

This accelerated approach would involve inactivating areas of the mouse chromosome known to contain sites of allelic loss previously identified to be associated with prostate cancer. Despite the fact that most human genes have direct homologues in the mouse, the structure of the mouse chromosomes are quite different from the human. Apart from the fact that human chromosomes are acrocentric and the mouse chromosomes are telocentric, the mouse and human genomes show many dissimilarities in the linear arrangements of genes. After years of chromosome mapping by a variety of techniques, a comparative physical and genetic map of the human and mouse chromosomes has emerged (12, 13). It is now possible to draw a direct comparison between subregions of a human and mouse chromosome. For example, human chromosome 8p is distributed in discrete blocks among two mouse chromosomes (mouse ch8 and mouse ch14). These blocks, or syntenic regions, are stable heritable units of genes. Within each chromosomal block, the arrangement of genes is very similar if not identical between mouse and human. Inactivation of these "human chromosome" blocks on the mouse chromosome would allow for physical interval testing to determine their role in prostate cancer. Furthermore by experimentally inducing LOH in the mouse, these syntenic blocks could provide a experimental directed approach to test how a particular region of a human chromosome might operate in the pathogenesis of prostate cancer.

Lessons from X-chromosome inactivation: developmental LOH.

A new technology is required to direct the functional inactivation of a chromosome and create experimental LOH in transgenic mice. We propose to create this technology based upon our basic pioneering work to define the process of X-chromosome inactivation. X-chromosome inactivation is the only known example in mammals of a developmentally regulated functional loss of heterozygosity. It is an example of an epigenetic developmental program that begins anew in the development of every female and represents a unique aspect of an individuals characteristics. X-inactivation is a particular type of epigenetic program operating in female mammals for the purpose of gene dosage compensation between the heterogametic sexes. (14, 15). X-inactivation allows a female embryo to functionally appear as monosomic for the X-chromosome despite the presence of two X-chromosomes. If this process did not occur it would be catastrophic to the developing female embryo with twice the number of X-linked genes as the male.

Two facts are established regarding the mechanism of X-inactivation: (1) a gene which encodes a nontranslateable RNA called *Xist* is necessary for X inactivation (16, 17). Early in development, prior to X-inactivation both male and female cells exhibit a low level of *Xist* expression (18, 19). Subsequent to implantation in female cells one X-chromosome is chosen and exhibits a significant induction of *Xist* expression (18, 19). Soon after *Xist* induction, genes in *cis* to the actively transcribed *Xist* are repressed for the lifetime of the cell (19-21). If the structural portion of the *Xist* gene is interrupted by homologous recombination, the X-chromosome containing this interrupted allele is incapable of undergoing X-inactivation (16, 17). This demonstrates the necessity of *Xist* for X-inactivation.

A region on the X-chromosome not much larger than the *Xist* gene is sufficient to direct the choice of which X-chromosome undergoes inactivation (19, 21). This DNA interval was first cloned in the form of a yeast artificial chromosome (YAC) by our laboratory and introduced into male embryonic stem cell lines derived (ES cells) (19). This 450 kb YAC was sufficient to be counted as an X-chromosome and direct inactivation on any chromosome in which it was integrated (19). Similarly a 40 kb cosmid was shown to sufficient to cause autosomal inactivation when the cosmid was autosomally integrated in *cis* in male ES cells (21).

Based upon the observation that a YAC or cosmid spanning *Xist* is necessary and sufficient for X-chromosome inactivation, a vector harboring the *Xist* gene under conditional control could operate to inactivate any chromosome in which it was integrated. To this end we have created a full length cDNA of the murine *Xist* and used it to create a vector in which the cDNA is under control of the tetracycline inducible operator system (22). This vector once integrated into the chromosome of choice would inactivate this chromosome once the *Xist* gene was to be activated. The activation of the *Xist* gene would be controlled by the exogenous administration of tetracycline at any point in development.

The common mouse has been used as a model system for experimental prostate cancer research. Despite the fact that prostate cancer is rarely observed among rodents several approaches to experimental modeling have been developed in the mouse. Three approaches have been described including 1) androgenic hormone stimulation with carcinogen exposure, 2) retroviral transduction and organ reconstitution and 3) transgenic targeting (23). In this proposal we will only address the transgenic approach to prostate cancer modeling. There have been essentially two transgenic models described which show prostate changes characteristic of human disease. These two models involve two different dominant oncogene/protein and two different promoters. The first system involves the use of the MMTV promoter and the Int-2 oncogene. The MMTV promoter is a glucocorticoid responsive viral promoter with favored expression in the mammary tissue of the lactating female. However, it has been shown that male transgenic mouse lines expressing the Int-2 gene under MMTV control results in dramatic epithelial hyperplasia of the prostate (24). The TRAMP model (transgenic adenocarcinoma mouse prostate) has also been described (25, 26). The TRAMP system involves the rat probasin promoter directing expression of the SV40 large T gene in a prostate specific manner. Several reports indicate that this model system recapitulates the aggressive course of human prostatic cancer (25-28). Prostatic intraepithelial neoplasia is observed in male mice of 8 - 12 weeks age. These lesions appear to progress to adenocarcinoma by 30 weeks and finally to distant metastases (25-28).

Preliminary Data

At the time of our Phase I grant submission we had finished the construction of what we believed to be a full length inducible cDNA version of the gene *Xist*. Our construction was guided by the published structures for the *Xist* genomic locus and RNA (34,35). During the final quality control steps, prior to introduction of our construct into ES cells and mice we started an exhaustive confirmation process to demonstrate not only that our *Xist* clone was identical to the published *Xist* structure, but that our clone was identical to the sequences found in the mouse germline. Much to our surprise (and dismay) despite the absolute identity of our clone the published structure, our clone contained discrepancies relative to the mouse genome. We struggled to discover the basis of these differences, and revealed that the published structure for *Xist* was in error and in need of revision. We discovered new structural data for the murine *Xist* gene. These data were published (36), and this paper demonstrates that the murine *Xist* transcript is at least 17.8 kb not 14.7 kb as previously reported. The new structure of the murine *Xist* gene described herein has seven exons, not six. Exon VII encodes an additional 3.1 kb of information at the 3'-end. Exon VII contains seven possible sites for polyadenylation, four of these sites are located in the newly discovered 3'-end. Consequently it is possible that several distinct transcripts may be produced through differential polyadenylation of a primary transcript. Alternative use of polyadenylation signals could result in size changes for Exon VII. Two major species of *Xist* are detectable by Northern analysis, consistent with differential polyadenylation.

Analyzing the human *XIST* structure has resulted in a strong structural correlation between the two organisms (37). Comparison of sequences from the genomic interval downstream to the 3' end of the human *XIST* gene against the human EST database brought to light a number of human EST sequences which are mapped to the region. Furthermore, PCR-amplification of human cDNA libraries and RNA-Fluorescence *In Situ* Hybridization (RNA-FISH) demonstrate that the human *XIST* gene has additional 2.8 kb downstream sequences which have not been documented as a part of the gene. These data show that the full length *XIST* cDNA is in fact 19.3 kb, not 16.5 kb as previously reported. The newly defined region contains an intron that may be alternatively spliced and seven polyadenylation signal sequences. Sequences in the newly defined region show overall sequence similarity with the 3' terminal region of mouse *Xist* and three subregions exhibit considerably high sequence conservation. Interestingly, the new intron spans the first two subregions that are absent in one of the two isoforms of mouse *Xist*. Taken together, we revise the structure of human *XIST* cDNA and compare cDNA structures between human and mouse *XIST*/*Xist*.

Finally, another paper has just been submitted documenting the structural explanation for the two RNA isoforms of murine *Xist* and the most reasonable mechanism for their production (38). To further define the molecular structures of the two *Xist* RNA isoforms, we performed northern blot analyses and RNase protection assay (RPA). Consistent with previous data, our northern blot analyses show that majority of the two transcripts are directed by P2 promoter. Additionally, the northern probe spanning 853 base pairs sequence 3' of *Xist* gave only one band indicating the two isoforms are different at their 3' termini. Probes for the RPA spanned either originally defined 3' terminus or two of the putative polyadenylation signals at the 3' termini. Results of the RPA experiments clearly show that *Xist* does not end at the previously proposed site, and the two isoforms are different in their sizes which we called short (S) and long (L) forms. The S form ends at 17030 nucleotides from the +1 transcription start site while the L form ends at 17873 nucleotides of the *Xist* cDNA. Therefore the S form is 843 nucleotides shorter than the L form. The following lines of evidences suggest that the difference in length at the 3' termini of the two *Xist* isoforms is due to differential polyadenylation, not splicing: 1) Only one band was detectable with the northern probes (pWS855, 859 and 860) spanning 3' of *Xist*. 2) RPA with P2 probe showed 3' termini of both S and L forms, and there are putative polyadenylation signals and hairpin structures close to these ends. 3) Analyses of splice site prediction program did not show any evidence of splicing in the sequence of L form. The extra sequence of the L form shares significant sequence similarity with our revision for the structure of the 3' region of human *XIST*. This suggests that mouse *Xist* depends on differential polyadenylation to generate the two isoforms while human *XIST* may depend on alternative splicing in addition to differential polyadenylation. The newly revised structure of *Xist* isoforms may play essential roles in the stability of *Xist* and the process of X inactivation.

Clearly, the schedule for our prostate project was derailed by the important findings of inaccuracies in the *Xist* structure. Instead of being able to start our transgenic experiments immediately we have spent the last year defining the actual structure of the *Xist* gene and RNA. In addition to defining the true structure for mouse and Human *Xist*/*XIST* it was necessary to rebuild our cDNA constructs. We now report that full length cDNAs for mouse *Xist* (17.8 kb) have been made.

In addition, using the revised *Xist* cDNA three types of expression constructs have also been made. First a vector that expresses *Xist* in a constitutive manner. Second,

two types of inducible *Xist* constructs have been made, 1) a tetracycline regulated form, and 2) an interferon inducible form.

All of three of these *Xist* expressing constructs have been introduced into somatic and ES cells by random transfection for the purpose of expression testing. The somatic cells used for these experiments are NIH 3T3 cells. These immortalized cells have been successfully transfected with the constructs. In each case the *Xist* constructs expressed RNA which we could detect both by Northern and RNA-FISH. The RNA-FISH results were quite exciting as the ectopically derived *Xist* was observed to "coat" or localize on the transgenic chromosome.

A number of different ES cell lines which inducibly express ectopic *Xist* have been produced. These cell lines were characterized to determine the chromosome into which the transgene had integrated. Our current results show random integrations into mouse 4, 5, 8, a number of additional ES cell lines have yet to be characterized. The integration into distal chromosome 8 is especially exciting as this chromosome is directly relevant to our proposed prostate cancer model of LOH.

Experiments to functionally characterize the transfected constructs have been undertaken. Each of the ES cell lines with *Xist* integrations, into either chromosome 4, 5, 8, have characterized by *Xist* localization, and cis-inactivation of gene expression. For chromosome 4 gene specific assay for *c-jun*, *Tlr4*, and *CDC42* were evaluated by RNA FISH. For chromosome 5 gene specific assay for beta-actin, ketokinase, and *CENP-A* were evaluated by RNA FISH. For chromosome 8 gene specific assay for *EIF-4E* and *Aprt* were evaluated by RNA FISH. In the transfected ES cell cultures, when *Xist* is expressed in an inducible manner it localizes to the transgenic chromosome and result in silencing of the genes in cis to the construct.

7) Key Research Accomplishments

- Redefinition of murine and human *Xist*/*XIST* gene structure
- Redefinition of murine and human *Xist*/*XIST* RNA structure
- Construction of 2 inducible versions of the murine *Xist* gene.
- Transfection of these constructs into mouse somatic and ES cells.
- Conditional expression of the inducible version of murine *Xist* in ES cells.
- Demonstrations that *Xist* cDNA alone will accomplish cis-silencing.
- Targeting of murine Chromosome 8 with conditional *Xist* construct.

8) Reportable Outcomes

Publications

1. Hong, Y-K, S.D. Ontiveros, C. Chen, W.M. Strauss. A New Structure for the Murine *Xist* Gene and its Relationship to Chromosome Choice/Counting during X-chromosome Inactivation. *Proc. Natl. Acad. Sci. U.S.A.* **96**(12): 6829-6834(1999).
2. Hong, Y-K, S.D. Ontiveros, W.M. Strauss. A revision of the human *XIST* gene organization and structural comparison to mouse *Xist*. *Mammalian Genome.* **11**:220-224(2000).
3. Memili, E. Y-K Hong, D. K. Kim, S.D. Ontiveros, W.M. Strauss. Murine *Xist* RNA isoforms are different at their 3'ends: a role for differential polyadenylation.. Submitted.

9) Conclusions

The scientific conclusions of this report are very optimistic. We have redefined the structure for mouse and human Xist/XIST gene and transcript. This transcript causes cis-inactivation of the chromosome from which it is expressed. Thus as we continue to construct the mouse strains harboring the Xist cDNA under probasin promoter control we have confidence that the expression of Xist will cause the desired result.

10) References

1. Dong, J.-T., W. B. Isaacs, J. T. Isaacs. 1997. Molecular advances in prostate cancer. *Current Opinion in Oncology*. 9: 101-107
2. Heidenberg, H. B., J. J. Bauer, D. G. McLeod, J. W. Moul, S. Srivastava. 1996. The role of p53 tumor suppressor gene in prostate cancer: a possible biomarker. *Urology*. 48: 971-979
3. Bookstein, R., G. S. Bova, D. MacGrogan, A. Levy, W. B. Isaacs. 1997. Tumor-suppressor genes in prostatic oncogenesis: a positional approach. *British Journal of Urology*. 79 s1: 28-36
4. Koivisto, P. A. 1996. Molecular genetics of prostate cancer. *Critical Reviews in Oncogenesis*. 7: 143-150
5. Bookstein, R., D. MacGrogan, S. G. Hilsenbeck, F. Sharkey, D. C. Allred. 1993. p53 is mutated in a subset of advanced-stage prostate cancers. *Cancer Research*. 53: 3369-3373
6. Navone, N. M., P. Troncoso, L. Pisters, et al. 1993. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. *J. National Cancer Institute*. 85: 1657-1669
7. Aprikian, A. G., A. S. Sarkis, W. R. Fair, Z. F. Zhang, Z. Fuks, C. Cordon-Cardo. 1994. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. *Journal of Urology*. 151: 1276-1280
8. Carter, H. B., S. Piantadosi, J. T. Isaacs. 1990. Clinical evidence for and implications of the multistep development of prostate cancer. *J. Urol.* 143: 742-746
9. Carter, B. S., C. M. Ewing, W. S. Ward, et al. 1990. Allelic loss of chromosomes 16q and 10q in human prostate cancer. *Proc. Natl. Acad. Sci. USA*. 87: 8751-8755

10. Cher, M. L., G. S. Bova, D. H. Moore, e. al. 1996. Genetic alterations in untreated prostate cancer metastases and androgen independent prostate cancer detected by comparative genomic hybridization and allelotyping. *Cancer Research*. 56: 3091-3102
11. Emmert-Buck, M. R., D. D. Vocke, R. O. Pozzatti, D. P.H., S. B. Jennings, C. D. Florence, Z. Zhuang, D. G. Bostwick, L. A. Liotta, W. M. Linehan. 1995. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. *Cancer Research*. 55: 2959-2962
12. Dietrich, W., H. Katz, S. E. Lincoln, H.-S. Shin, J. Friedman, N. C. Dracopoli, E. S. Lander. 1992. A Genetic Map of the Mouse Suitable for Typing Intraspecific Crosses. *Genetics*. 131: 423-447
13. Copeland, N. G., N. A. Jenkins. 1991. Development and applications of a molecular genetic linkage map of the mouse genome. *Trends in Genetics*. 7: 113-118
14. Lyon, M. F. 1961. Gene Action in the X-chromosome of the mouse (Mus musculus L.). *Nature*. 190: 372-373
15. Lyon, M. F. 1963. Attempts to test the inactive-X theory of dosage compensation in mammals. *Genet. Res. (Camb)*. 4: 93-103
16. Penny, G. D., G. F. Kay, S. A. Sheardown, S. Rastan, N. Brockdorff. 1996. Requirement for *Xist* in X chromosome inactivation. *Nature*. 379: 131-137
17. Marahrens, Y., B. Panning, J. Dausman, W. Strauss, R. Jaenisch. 1997. *Xist*-deficient mice are defective in dosage compensation but not spermatogenesis. *Genes and Development*. 11: 156-166
18. Beard, C., E. Li, R. Jaenisch. 1995. Loss of methylation activates *Xist* in somatic but not in embryonic cells. *Genes and Development*. 9: 2325-2334
19. Lee, J. T., W. M. Strauss, J. A. Dausman, R. Jaenisch. 1996. A 450 Kb Transgene displays properties of the mammalian X-inactivation center. *Cell*. 86: 83-94
20. Lee, J. T., R. Jaenisch. 1997. Long-range cis effects of ectopic X-inactivation centres on a mouse autosome. *Nature*. 386: 275-279
21. Herzing, L. B. K., J. T. Romer, J. M. Horn, A. Ashworth. 1997. *Xist* has properties of the X-chromosome inactivation centre. *Nature*. 386: 272-275
22. Gossen, M., H. Bujard. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. *Proc. Natl. Acad. Sci. USA*. 89: 5547-5551
23. Buttyan, R., K. Slawin. 1993. Rodent models for targeted onogenesis of the prostate gland. *Cancer and Metastasis Reviews*. 12: 11-19

24. Muller, W. J., F. S. Lee, C. Dickson, G. Peters, P. Pattengale, P. Leder. 1990. The int-2 gene product acts as an epithelial growth factor in transgenic mice.. *EMBO Journal*. 9: 907-913

25. Greenberg, N. M., F. J. DeMayo, P. C. Sheppard, R. Barrios, R. Lebovitz, M. Finegold, R. Angelopoulou, J. G. Dodd, M. L. Duckworth, J. M. Rosen, e. al. 1994. The rat probasin promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. *Molecular Endocrinology*. 8: 230-239

26. Greenberg, N. M., F. DeMayo, M. J. Finegold, D. Medina, W. D. Tilley, J. O. Aspinall, G. R. Cunha, A. A. Donjacour, R. J. Matusik, J. M. Rosen. 1995. Prostate cancer in a transgenic mouse. *Proc. Natl. Acad. Sci. USA*. 92: 3439-3443

27. Foster, B. A., J. R. Gingrich, E. D. Kwon, C. Madias, N. M. Greenberg. 1997. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. *Cancer Research*. 57: 3325-3330

28. Gingrich, J. R., R. J. Barrios, R. A. Morton, B. F. Boyce, F. J. Demayo, M. J. Finegold, A. R., J. M. Rosen, J. M. Greenberg. 1996. Metastatic prostate cancer in a transgenic mouse. *Cancer Research*. 56: 4096-4102

29. Chalfie, M., Y. Tu, G. Euskirchen, W. W. Ward, D. C. Prasher. 1994. Green flourescent protein as a marker for gene expression. *Science*. 263: 802-805

30. Yan, Y., P. C. Sheppard, S. Kasper, L. Lin, S. Hoare, A. Kapoor, J. G. Dodd, M. L. Duckworth, R. J. Matusik. 1997. Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. *Prostate*. 32: 129-139

31. Johnson, C. V., R. H. Singer, J. B. Lawrence. 1991. Fluorescent detection of nuclear RNA and DNA: Implications for genome organization. *Methods in Cell Bio*. 35: 75-99

32. Lawrence, J. B., R. H. Singer, L. M. Marselle. 1989. Highly Localized Distribution of Specific Transcripts Within Interphase Nuclei Visualized by in situ Hybridization. *Cell*. 57: 493-502

33. Lawrence, J. B., R. H. Singer, J. A. McNeil. 1990. Interphase and Metaphase Resolution of Different Distances with the Human Dystrophin Gene. *Science*. 249: 928

34. Brockdorff, N., Ashworth, A., Kay, G. F., McCabe, V. M., Norris, D. P., Cooper, P. J., Swift, S. & Rastan, S. (1992) *Cell* 71, 515-526.

35. Brockdorff, N., Ashworth, A., Kay, G. F., Cooper, P., Smith, S., McCabe, V. M., Norris, D. P., Penny, G. D., Patel, D. & Rastan, S. (1991) *Nature* 351, 329-331.

36. Hong, Y-K, S.D.Ontiveros, C.Chen, W.M. Strauss. A New Structure for the Murine *Xist* Gene and its Relationship to Chromosome

Choice/Counting during X-chromosome Inactivation. *Proc. Natl. Acad. Sci. U.S.A.* **96**(12): 6829-6834(1999).

37. Hong, Y-K, S.D. Ontiveros, W.M. Strauss. A revision of the human *XIST* gene organization and structural comparison to mouse *Xist*. . *Mammalian Genome*. **11**:220-224(2000).

38. Memili, E. Y-K Hong, D. K. Kim, S.D. Ontiveros, W.M. Strauss. Murine *Xist* RNA isoforms are different at their 3'ends: a role for differential polyadenylation.. Submitted

11) Appendicies

N/A